Health Trials

About this trial

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Eligibility criteria

Qualifiers

Age 18 years or older on the day of consent.

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

Adequate organ and marrow function.

Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • XB010
  • Pembrolizumab

Treatment groups

396 Participants
are divided into 3 treatment groups

Locations

20
United Kingdom
University Hospitals of Leicester NHS TrustLE1 5WW, Leicester United Kingdom
Sarah Cannon Research Institute LondonW1G 6AD, London United Kingdom
University College London Hospitals NHS Foundation TrustW1T 7HA, London United Kingdom
The Christie NHS Foundation TrustM20 4BX, Manchester United Kingdom

Sponsors and collaborators

Exelixis

Lead sponsor

Source ClinicalTrials.gov